Core of the Antiviral Drug Discovery and Development Center (ADSC) will provide a key role in leadership, communication, coordination and oversight ofthe projects and cores, and stimulate collaboration and synergy between the projects. Operationally, it is in charge of fiscal and contractual management of the center and will plan and implement activities, such as meetings of the Executive Committee (EC), External Scientific Advisory Board (EAB), and an annual meeting of all projects and cores. In addition, it will manage the inter-institutional cooperative agreements. The core is also responsible for managing the solicitation and review of Supplemental Research Projects applications, such as those for additional product development and support for IND-enabling studies. Finally, the core will facilitate dissemination of progress and discoveries to the public.
The Administrative Core will provide information and assistance to Antiviral Drug Discovery and Development Center project investigators who are developing potential therapies for emerging infections such as West Nile virus and influenza. The Core will also assist with preparing reports and publications that will allow public access to data and results that are collected as part of the scientific research.
|Mounce, Bryan C; Cesaro, Teresa; Moratorio, Gonzalo et al. (2016) Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses. J Virol 90:9683-9692|
|Morrison, Clayton R; Plante, Kenneth S; Heise, Mark T (2016) Chikungunya Virus: Current Perspectives on a Reemerging Virus. Microbiol Spectr 4:|
|McCarthy, Mary K; Morrison, Thomas E (2016) Chronic chikungunya virus musculoskeletal disease: what are the underlying mechanisms? Future Microbiol 11:331-4|
|Rasmussen, Lynn; White, E Lucile; Bostwick, James R (2016) Acoustic Droplet Ejection Applications for High-Throughput Screening of Infectious Agents. J Lab Autom 21:188-97|
|Everts, Maaike; Suto, Mark J; Painter, George R et al. (2016) Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective. Future Virol 11:187-195|
|Haese, Nicole N; Broeckel, Rebecca M; Hawman, David W et al. (2016) Animal Models of Chikungunya Virus Infection and Disease. J Infect Dis 214:S482-S487|
|Broeckel, Rebecca; Haese, Nicole; Messaoudi, Ilhem et al. (2015) Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model). Pathogens 4:662-81|
|Chiang, Cindy; Beljanski, Vladimir; Yin, Kevin et al. (2015) Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists. J Virol 89:8011-25|
|Sali, Tina M; Pryke, Kara M; Abraham, Jinu et al. (2015) Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog 11:e1005324|
|Mainou, Bernardo A; Ashbrook, Alison W; Smith, Everett Clinton et al. (2015) Serotonin Receptor Agonist 5-Nonyloxytryptamine Alters the Kinetics of Reovirus Cell Entry. J Virol 89:8701-12|
Showing the most recent 10 out of 15 publications